TRINITY BIOTECH PLC-SPON ADR (TRIB)
US8964385046 - ADR
Taking everything into account, TRIB scores 2 out of 10 in our fundamental rating. TRIB was compared to 196 industry peers in the Health Care Equipment & Supplies industry. TRIB has a bad profitability rating. Also its financial health evaluation is rather negative. TRIB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year TRIB has reported negative net income.
TRIB had a negative operating cash flow in the past year.
In the past 5 years TRIB reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: TRIB reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -40.42%, TRIB is not doing good in the industry: 61.22% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.42% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-28.06%
ROA(5y)-22.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TRIB has a worse Gross Margin (34.22%) than 68.37% of its industry peers.
In the last couple of years the Gross Margin of TRIB has declined.
The Profit Margin and Operating Margin are not available for TRIB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.22% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.44%
GM growth 5Y-4.32%
2. Health
2.1 Basic Checks
TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TRIB has been reduced compared to 1 year ago.
Compared to 5 years ago, TRIB has less shares outstanding
TRIB has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.49, we must say that TRIB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.49, TRIB is in line with its industry, outperforming 44.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.49 |
ROIC/WACCN/A
WACC10.38%
2.3 Liquidity
A Current Ratio of 2.60 indicates that TRIB has no problem at all paying its short term obligations.
TRIB has a Current ratio (2.60) which is in line with its industry peers.
TRIB has a Quick Ratio of 1.27. This is a normal value and indicates that TRIB is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of TRIB (1.27) is worse than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
TRIB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.80%.
The Revenue for TRIB has decreased by -20.71% in the past year. This is quite bad
Measured over the past years, TRIB shows a very negative growth in Revenue. The Revenue has been decreasing by -10.14% on average per year.
EPS 1Y (TTM)-12.8%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q48.73%
Revenue 1Y (TTM)-20.71%
Revenue growth 3Y-17.71%
Revenue growth 5Y-10.14%
Revenue growth Q2Q-25.57%
3.2 Future
Based on estimates for the next years, TRIB will show a very strong growth in Earnings Per Share. The EPS will grow by 47.29% on average per year.
The Revenue is expected to grow by 12.28% on average over the next years. This is quite good.
EPS Next Y49.15%
EPS Next 2Y47.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year14.92%
Revenue Next 2Y12.28%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TRIB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRIB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TRIB's earnings are expected to grow with 47.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.29%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for TRIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRINITY BIOTECH PLC-SPON ADR
NASDAQ:TRIB (4/19/2024, 8:30:00 AM)
1.84
-0.04 (-2.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.06M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.42% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.22% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.96
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.6 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-12.8%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y49.15%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-20.71%
Revenue growth 3Y-17.71%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y